MedTrace Logo

Alzheimer's Disease Neuroimaging Initiative 3

NCT02854033 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1141

Last updated 2026-03-11

No results posted yet for this study

Summary

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

Conditions

  • Mild Cognitive Impairment (MCI)
  • Alzheimer's Disease (AD)

Sponsors & Collaborators

  • Northern California Institute of Research and Education

    collaborator OTHER

  • National Institute on Aging (NIA)

    collaborator NIH

  • Alzheimer's Therapeutic Research Institute

    collaborator OTHER

  • University of Southern California

    lead OTHER

Principal Investigators

  • Michael W. Weiner, MD · University of California, San Francisco

  • Paul Aisen, MD · USC Alzheimer's Therapeutic Research Institute (ATRI)

  • Ronald Peterson, MD, PHD · Mayo Clinic

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-02
Primary Completion
2024-05-28
Completion
2024-05-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02854033 on ClinicalTrials.gov